Ignite Creation Date:
2025-12-24 @ 7:24 PM
Ignite Modification Date:
2026-03-08 @ 11:00 PM
Study NCT ID:
NCT02272803
Status:
COMPLETED
Last Update Posted:
2022-06-22
First Post:
2014-10-21
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
Sponsor:
Bristol-Myers Squibb
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CA204-116
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |